Treatment of pain following abdominal
laparoscopic surgery 304 III Enrolling
Adult safety 351 III Enrolling
Pediatric safety 352 III Enrolling
Pediatric pharmacokinetics 102 I Enrolling
(1) Conducted by Bristol-Myers Squibb Company
Omigard(TM) Clinical Program Update
o Cadence currently expects to announce top-line data from CLIRS in the
second half of 2008 and, if the results are positive, submit an NDA for
Omigard to the FDA in the first half of 2009.
Conference Call and Webcast on May 6, 2008 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time)
Cadence management will host a conference call on May 6, 2008 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) and interested investors may participate in the conference call by dialing 877-675-4750 (domestic) or 719-325-4865 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
principally for use in the hospital setting. The company currently has two
Phase III product candidates in development, Acetavance(TM) (intravenous
acetaminophen) for the treatment of acute pain and fever, and Omigard(TM)
(omiganan pentahydrochloride 1% topical gel) for the prevention of
catheter-related infections. For more information about Cadence's pipeline,
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved